PAVmed Inc.
PAVMNasdaqHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $71,000 | $3.0M | $2.5M | $377,000 | $500,000 | — |
| Operating income | −$21.8M | −$44.5M | −$68.8M | −$91.1M | −$54.4M | −$23.4M |
| Net income | $401,000 | $39.8M | −$64.2M | −$89.0M | −$50.3M | −$34.3M |
| Total assets | $38.8M | $30.7M | $33.1M | $54.0M | $87.0M | $19.8M |
| Total liabilities | $16.5M | $37.7M | $57.1M | $43.0M | $7.6M | $20.3M |
| Equity | $34.0M | −$2.5M | −$53.8M | −$9.7M | $61.7M | $1.9M |
| EPS (diluted) | $-5.63 | $0.50 | $-9.16 | $-15.03 | $-0.65 | — |
| Shares out. | 16.8M | 11.5M | 98.4M | 87.7M | 82.5M | 44.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −30712.7%
- Net margin
- 564.8%
- Return on equity
- 1.2%
- Return on assets
- 1.0%
- Return on capital (ROCE)
- −91.0%
- Liabilities / assets
- 42.5%
- Debt / equity
- 0.49×
- Book value / share
- $2.02
- Revenue growth (YoY)
- −97.6%
- Net income growth (YoY)
- −99.0%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -25.42distress
- Accruals / assets
- 14.4%high accruals
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Revenue declined year-over-year
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2022
- NT 10-Qmissed a reporting deadline ↗Nov 16, 2021
- NT 10-Kmissed a reporting deadline ↗Mar 30, 2020
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2019
- NT 10-Qmissed a reporting deadline ↗May 15, 2018
- NT 10-Qmissed a reporting deadline ↗May 15, 2017
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Two Seas Capital LpPassive (13G)May 15, 2026
- First Manhattan Co. Llc.Passive (13G)May 14, 2026
- Ayrton Capital LlcPassive (13G)May 11, 2026
- Tasso Partners, LlcPassive (13G)Apr 14, 2026
- Scopia Holdings LlcPassive (13G)Apr 13, 2026
- Aklog LishanActivist (13D)Apr 9, 2026
- Nagelberg David SPassive (13G)Apr 8, 2026
- Dols Scott V.Passive (13G)Apr 8, 2026
- Kallman CraigPassive (13G)Apr 3, 2026
- Sargent Investment Group, LlcPassive (13G)Aug 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Lee Victoria Tou-HoOfficer — Chief Medical Officer | Apr 2, 2026 | Grant | 70,000 | $0.00 |
| Aklog LishanOfficer — Chairman and CEO | Apr 2, 2026 | Grant | 350,000 | $0.00 |
| Mcgrath Dennis MOfficer — President and CFO | Apr 2, 2026 | Grant | 180,000 | $0.00 |
| Glennon Michael JDirector | Apr 2, 2026 | Grant | 13,930 | $0.00 |
| Baxter Timothy EDirector | Apr 2, 2026 | Grant | 13,930 | $0.00 |
| White DebraDirector | Apr 2, 2026 | Grant | 13,930 | $0.00 |
| Sparks Ronald MDirector | Apr 2, 2026 | Grant | 13,930 | $0.00 |
| Agrawal SundeepDirector | Apr 2, 2026 | Grant | 13,930 | $0.00 |
| Gordon Michael AdamOfficer — General Counsel | Apr 2, 2026 | Grant | 110,000 | $0.00 |
| O'Neil ShaunOfficer — Chief Operating Officer | Apr 2, 2026 | Grant | 110,000 | $0.00 |
| Sparks Ronald MDirector | Sep 30, 2025 | Grant | 150,000 | $0.00 |
| White DebraDirector | Sep 30, 2025 | Grant | 150,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 13,031 | 1.0 | -26.5% |
| Apr 30, 2026 | 17,722 | 1.2 | +16.3% |
| Apr 15, 2026 | 15,238 | 1.5 | -35.1% |
| Mar 31, 2026 | 23,477 | 1.4 | +1.0% |
| Mar 13, 2026 | 23,246 | 1.1 | -53.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureMay 15, 2026
- Results of operations · Regulation FD disclosureMar 30, 2026
- Director / officer change · Amended charter or bylaws · Shareholder voteMar 27, 2026
- Entered a material agreement · Terminated a material agreement · New financial obligation · Unregistered equity sale · Modified shareholder rights · Amended charter or bylaws · Regulation FD disclosureFeb 4, 2026
- Other material eventJan 23, 2026
- Modified shareholder rights · Amended charter or bylaws · Regulation FD disclosureDec 30, 2025
- Shareholder voteDec 5, 2025
- Results of operations · Regulation FD disclosureNov 13, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13GMay 15, 2026
- 8-KMay 15, 2026
- 10-QFORM 10-QMay 14, 2026
- SCHEDULE 13GMay 14, 2026
- SCHEDULE 13G/AMay 11, 2026
- DEF 14AApr 30, 2026
- DEFA14AApr 30, 2026
- ARSApr 30, 2026
- EFFECTApr 29, 2026
- 424B3Apr 29, 2026
- CORRESPApr 27, 2026
- UPLOADApr 24, 2026
- S-3Apr 21, 2026
- SCHEDULE 13G/AApr 14, 2026
- 4STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESApr 13, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.